Tarsus Pharmaceuticals, Inc. Common Stock
$78.09
-$0.94 (-1.19%)
$77.33Day Range$79.10
Key Statistics
Market Cap
$3.65B
Shares Outstanding
46.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 16, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$78.67
Day High
$79.10
Day Low
$77.33
Volume
711.0K
VWAP
$78.13
Prev Close
$79.03
Transactions
--
Acc. Volume
--
About Tarsus Pharmaceuticals, Inc. Common Stock
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836370 employees15440 LAGUNA CANYON ROAD, IRVINE, CA, 92618(949) 409-9820IPO Oct 16, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001819790
- Composite FIGI
- BBG00RB9BNQ7
- Share Class FIGI
- BBG00RB9BNR6
- Ticker Root
- TARS
- SIC Code
- 2836
About Tarsus Pharmaceuticals, Inc. Common Stock (TARS) Stock
Tarsus Pharmaceuticals, Inc. Common Stock (TARS) closed the 2026-09-18 session at $78.09, down 1.19% versus the previous close (-0.94). The stock opened at $78.67 and traded between $77.33 and $79.10 during that session. Session trading volume was 711K shares. The volume-weighted average price (VWAP) is $78.13.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
Tarsus Pharmaceuticals, Inc. Common Stock has a market capitalization of $3.65 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. TARS is listed on the XNAS exchange. The company employs approximately 370 people. Tarsus Pharmaceuticals, Inc. Common Stock is headquartered in IRVINE, CA. The recorded listing date is 2020-10-16.
On this page you can find market TARS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.